Abstract 1237P
Background
Incidence of melanoma, glioma and gastrointestinal stromal tumor (GIST) is increasing worldwide, which results in public health problems. The increasing number of markers that are tested in a correct diagnostic procedure makes gene-targeted, next-generation sequencing (NGS) a powerful tool in routine pathology practice. However, special panels for melanoma, glioma and GIST (MGG) are scarce. In this study, we designed and validated a NGS panel which included 1064 amplicons in 57 genes covering targetable alterations associated with the diagnosis and potential treatment response of MGG.
Methods
Based on extensive literature review and integrating TCGA and COSMIC databases, we developed MGG panel that is associated with diagnosis and potential treatment response of MGG. We validated this NGS panel including accuracy, reproducibility/repeatability, limit of detection (Lod), a comparative analysis between conventional methodologies and NGS using reference mutated DNA, tumor and normal tissue samples that were previously characterized.
Results
The NGS panel achieved 100% accuracy for mutation detection. Intra-experiment repeatability and inter-experiment reproducibility showed 100% concordance for one reference mutated DNA and four tumor samples, and a high correlation was observed between inter- and intra-sequencing runs. The Lod was established at a 2% variant allele frequency (VAF) for single-nucleotide variants (SNVs) and insertion-deletions (indels), and the threshold for copy number amplification and deletion was 3 and 1.4, respectively. Subsequently, we performed a comparative analysis between conventional methodologies - such as Sanger sequencing or fluorescence in situ hybridization - and NGS on 119 tumor and normal tissue samples that had been previously tested in our laboratory. The comparison between conventional methodologies and NGS showed high concordance (116/119, 97.5%).
Conclusions
This NGS panel is an accurate and sensitive method. Moreover, it is a rapid and cost-effective approach that can simultaneously detect different genetic alterations useful for the diagnosis, prognosis and treatment of patients with melanoma, glioma or GIST.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fudan university Shanghai Cancer Center.
Funding
Has not received any funding.
Disclosure
D. Zhao, Y. Jiao, X. Shi: Financial Interests, Personal, Full or part-time Employment: Zhengu Biotech Ltd. All other authors have declared no conflicts of interests.
Resources from the same session
1241P - Decoding the glycan code: Pioneering early detection of non-small cell lung cancer through glycoproteomics
Presenter: Kai He
Session: Poster session 14
1242P - Implementing functional precision oncology in real-world patients: Translating extensive in vitro data into personalized treatment combining genetics and functional assays
Presenter: Dörthe Schaffrin-Nabe
Session: Poster session 14
1243P - Ocular surface squamous neoplasia early diagnosis using an AI-empowered autofluorescence multispectral imaging technique
Presenter: Abbas HABIBALAHI
Session: Poster session 14
1244P - AI-based accurate PD-L1 IHC assessment in non-small cell lung cancer across multiple sites and scanners
Presenter: Ramona Erber
Session: Poster session 14
1245P - A lymph nodal staging assessment model for various histologic types of small intestinal tumors
Presenter: YOUSHENG LI
Session: Poster session 14
1246P - Detection of alternative lengthening of telomeres (ALT) across cancer types based on tumor-normal multigene panel sequencing
Presenter: Juan Blanco Heredia
Session: Poster session 14
1247P - A detection model for EGFR mutations in lung adenocarcinoma patients based on volatile organic compounds
Presenter: Yunpeng Yang
Session: Poster session 14
1248P - Development of a high performance and noninvasive diagnostic model using blood cell-free microRNAs for multi-cancer early detection
Presenter: Jason Zhang
Session: Poster session 14
1249P - Whole genome sequencing-based cancer diagnostics in routine clinical practice: An interim analysis of two years of real-world data
Presenter: Jeffrey van Putten
Session: Poster session 14
1250P - Assessing lung carcinoma: A retrospective study on volume evaluation, consolidation and infiltration using chest OMX
Presenter: Swarnambiga Ayyachamy
Session: Poster session 14